ArticleWorld journal of gastrointestinal pharmacology and therapeutics2026
Hemodynamic safety of remimazolam
Article in World journal of gastrointestinal pharmacology and therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEndoscopy and colonoscopy are gastrointestinal procedures which are frequently performed in diagnosing conditions like gastrointestinal inflammatory disorders, strictures, or malignancy. Sedation in these procedures is necessary for patient comfort and successful completion of the procedure, especially in elderly people. This meta-analysis compares the efficacy and safety profiles of two commonly used sedatives, propofol and remimazolam, a new agent with a potentially safer profile.
aimTo compare the efficacy and safety profiles of two commonly used sedatives in the elderly population, propofol and remimazolam, a new agent with a potentially safer profile.
methodsPubMed, Google Scholar, and Cochrane Library databases were searched from inception until 2025 to identify studies comparing remimazolam to propofol in elderly patients undergoing gastrointestinal endoscopic procedures. Statistical analyses were performed using RevMan with a random-effects model. Heterogeneity was assessed using the
resultsOur study involved 10 randomized controlled trials with a total of 1994 patients, 997 (50.0%) of whom were in the remimazolam group and 997 (50.0%) were in the propofol group. Hypotension, the primary outcome, occurred significantly less often in patients receiving remimazolam (risk ratio = 0.48, 95% confidence interval: 0.38-0.61;
conclusionRemimazolam appears to be a safer alternative to propofol for elderly patients undergoing gastrointestinal endoscopy. Remimazolam was associated with a lower incidence of hypotension, bradycardia, respiratory depression, and injection-site pain. The recovery time and incidence of nausea and vomiting were similar after administration of either drug. Further high-quality trials are warranted to confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.